Infliximab: Advances in the Treatment of Psoriasis and Psoriatic Arthritis

Abstract

Get full access to this article

View all access options for this article.

References

Baker

Epidemiologic aspects of psoriasis and arthritis.

Br J Dermatol 1966; 78.

Chaudhari

, Romano

, Murpy

L.D.

, Dooley

L.T.

, Baker

D.G.

, Gottlieb

A.B.

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial.

Lancet 2001; 357.

Choy

E.H.

Cytokine pathways and joint inflammation in rheumatoid arthritis.

N Engl J Med 2001; 344(12).

Ettehadi

, Greaves

M.W.

, Wallach

. Elevated tumour necrosis factor-alpha biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146–151.

Felson

D.T.

, Anderson

J.J.

, Boers

. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38(6).

Gottlieb

A.B.

Psoriasis-immnopathology and immunomodulation.

Dermatol Clin North Am 2001; 19(4).

Maini

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Lancet 1999; 354(9194).

Nickoloff

B.J.

Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha, in psoriasis.

Am J Pathol 1991; 138(1).

Norris

D.A.

Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets.

J Invest Dermatol 1990; 95(6 Suppl).

10.

Ogilvie

A.L.F.

, Antoni

, Dechant

, Manger

, Kalden

J.R.

, Schuler

, Luftl

Treatment of psoriatic arthritis with antitumour necrosis factor-a antibody clears skin lesions of psoriasis resistant to treatment with methotrexate.

Br J Dermatol 2001; 144.

11.

C.J.

Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions.

J Am Acad Dermatol 2000; 42(5 Pt 1).

12.

Present

D.H.

Infliximab for the treatment of fistulas in patients with Crohn's disease.

N Engl J Med 1999; 340(18).

13.

Scallon

B.J.

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.

Cytokine 1995; 7(3).

14.

Targan

S.R.

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

N Engl J Med 1997; 337(15).